OncoLab

News

Progress Report Issue No. 2

2025.12.19

R&D Pipeline

home en R&D Pipeline

We engineer bispecific inspired multi mechanisms and ADC like mechanisms—through formulation

R&D Pipeline

2025
2026
2027
2028
2029

ANGel-TNBC01/02
First-gen. ANGel
Clinical validation
Triple Negative Breast Cancer
(TNBC)
Preclinical package
Clinical exploration prep
Clinical entry readiness
Quality / safety framework
Early clinical exploration
Partnering initiated
Clinical expansion
Co-dev / licensing track
Technology transfer
Indication expansion

ANGel-PSC01/02
Oncology pivot
Indication exploration
Prostate
Cancer
Initial efficacy exploration
Expansion feasibility
Cross-tumor evaluation
Priority indications
Pivot indication finalized
Strategy decision
Partner-driven roadmap
Transition planning
Partnering pathway
Integration decision

ANGel-Dox01,02
Next-gen. pipeline
Co-delivery
Triple Negative Breast Cancer
(TNBC)
Loading & release established
In vitro validation
In In vivo PoC
Delivery comparison
PoC package completed
Partner validation
Co-dev / licensing progress
Combination expansion
Strategic partnership
Platform expansion

Clinical Validation Strategy
for the ANGel Platform
Stage
(Complexity)
Level 1
(low)
Level 2
(middle)
Level 3
(high)
Level 4
(very high)
Open-innovation
Licensing (2027~)

Objective
Immune-model PoC
IIT early clinical
Domestic expansion
Global / Co-development

Cost(US$) / Time
0.2M / 6 mo
0.6M / 12 mo
2M / 18 mo
3M / 24 mo

Lead Program: TNBC — Clinical Entry Proof Package
TNBC is the first program designed to deliver a clinical entry “proof package” for ANGel. The focus is to assemble a dataset that partners and regulators can diligence quickly—by integrating:
- GLP toxicology (Good Laboratory Practice)
- Humanized mouse efficacy PoC (proof of concept)
- CMC standardization (Chemistry, Manufacturing & Controls: specs + reproducibility)
2026 key deliverables
- ANGel prototypes (multi antibody configuration + small molecule payload), plus reproducibility confirmation
- A quantitative QC & performance package including: particle size/PDI, conjugation & loading, release profile, stability
Mechanism Strategy: “Bispecific like + ADC like” — Built Through Formulation
ANGel’s mechanism strategy is to use existing antibodies and small molecule anticancer drugs—without redesigning the biologic—to express two complementary mechanism paths within a single formulation:

What we aim to prove
- Bispecific like multi mechanism, implemented at the formulation level through multi antibody combinations
- ADC like mechanism, implemented through a payload strategy (small molecule loading + tuned release profile)
- Tech transfer–ready standardization
Partnering Track: Data driven Co Development → Option to License
Collaboration is designed as a staged conversion—not a one off conversation:
Using the GLP + PoC dataset generated in 2026, partnering discussions with domestic and global pharma are re activated, with a roadmap to convert into option agreements or co development deals in 2027.

Timeline (compressed): Data → Deal → Clinic

Proof Year

2026

ANGel TNBC application patent filed
ANGel GLP tox results
Humanized mouse efficacy
Series A funding

Deal Year

2027

Execute option / co‑development agreements
Global BD achievement
ANGel IND filing
Investigator-initiated & Phase 1 clinical trial

Clinical-entry Year

2028

Complete domestic Phase 1
Pursue strategic partnerships and out‑licensing
Series B funding
Advance a global Phase 1 strategy

2026 | Proof Year — Build decision grade data
- Lock CQAs and platform specs (CQA finalization and standardization)
- Complete GLP toxicology (regulatory grade safety package)
- Deliver humanized mouse efficacy PoC, including biomarker readouts
- Demonstrate repeat manufacturing and batch to batch reproducibility
2027 | Deal Year — Become tech transfer ready, convert partnering
- 3rd round global partnering meetings → collaboration conversion
- Execute option / co development agreements (structured deal pathways)
- Finalize the Phase 1 entry package (IND/CMC linked readiness)
- Initiate investigator sponsored and domestic Phase 1 pathways (as planned)
2028 | Clinical Execution Year — Phase 1 completion, global expansion
- Complete domestic Phase 1 and advance a global Phase 1 strategy
- Scale the ANGel platform collaboration program (broader assets / combinations)
- Pursue strategic partnerships and out licensing tied to clinical learnings

R&D Pipeline

R&D Pipeline

Lead Program: TNBC — Clinical Entry Proof Package

Mechanism Strategy: “Bispecific like + ADC like” — Built Through Formulation

Partnering Track: Data driven Co Development → Option to License

Timeline (compressed): Data → Deal → Clinic

2026 | Proof Year — Build decision grade data

2027 | Deal Year — Become tech transfer ready, convert partnering

2028 | Clinical Execution Year — Phase 1 completion, global expansion

Contact Us

OncoLaB Hiring Guide